ME | 23andMe Holding Co. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	4.57 - 4.78
52 Week Range	4.57 - 20.40
Beta	0.83
Implied Volatility	99.19%
IV Rank	-2.82%
Day's Volume	118,260
Average Volume	195,762
Shares Outstanding	25,840,002
Market Cap	121,448,009
Sector	Healthcare
Industry	Medical - Diagnostics & Research
IPO Date	2020-11-23

Valuation
Profitability
Growth
Health
P/E Ratio	-0.18
Forward P/E Ratio	N/A
EPS	-26.20
1YR Price Target	6.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	560
Country	USA
Website	ME

23andMe is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. More than 80% of 23andMe customers voluntarily elect to share their de-identified genetic data with the company, which is used to develop future reports. In 2018, GlaxoSmithKline made an equity investment in the company, entering a five-year collaborative agreement with 23andMe to develop drug candidates.

ME's peers: IDXX, TWST, GH, DMTK, A, TMO, NVTA, DHR, BIOC, SQL, HTGM, GENE, ILMN, WAT, OPK

*Chart delayed

Analyzing fundamentals for ME we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see ME Fundamentals page.

Watching at ME technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on ME Technicals page.